2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

DINESH KHANNA, JOHN D. FITZGERALD, PUJA P. KHANNA, SANGMEE BAE, MANJIT K. SINGH, TUHINA NEOGI, MICHAEL H. PILLINGER, JOAN MERILL, SUSAN LEE, SHRADDHA PRAKASH, MARIAN KALDAS, MANEESH GOGIA, FERNANDO PEREZ-RUIZ, WILL TAYLOR, FREDERIC LIOTE, HYON CHOI, JASVINDER A. SINGH, NICOLA DALBETH, SANFORD KAPLAN, VANDANA NIYYAR, DANIELLE JONES, STEVEN A. YAROWS, BLAKE ROESSLER, GAIL KERR, CHARLES KING, GERALD LEVY, DANIEL E. FURST, N. LAWRENCE EDWARDS, BRIAN MANDELL, H. RALPH SCHUMACHER, MARK ROBBINS, NEIL WENGER, AND ROBERT TERKELTAUB

[1]  M. Dougados,et al.  EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2004, Annals of the rheumatic diseases.

[2]  N. Chaiyakunapruk,et al.  Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis , 2011, BMC Medical Genetics.

[3]  C. Fernández,et al.  Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. , 1999, The Journal of rheumatology.

[4]  N. McGill.  6. Gout and other crystal arthropathies , 1997, The Medical journal of Australia.

[5]  Jeffrey R Curtis,et al.  2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.

[6]  J. Nolla,et al.  Correction of Allopurinol Dosing Should Be Based on Clearance of Creatinine, but Not Plasma Creatinine Levels: Another Insight to Allopurinol-Related Toxicity , 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[7]  C. Weel,et al.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.

[8]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[9]  K. Chien,et al.  Relationship between dietary patterns and serum uric acid concentrations among ethnic Chinese adults in Taiwan. , 2012, Asia Pacific journal of clinical nutrition.

[10]  A. So,et al.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.

[11]  R. Terkeltaub.  Clinical practice. Gout. , 2003, The New England journal of medicine.

[12]  K. Hande.  Evaluation of a Thiazide‐Allopurinol Drug Interaction , 1986, The American journal of the medical sciences.

[13]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[14]  H. Bueno,et al.  NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies , 2011, PloS one.

[15]  J. Levin,et al.  Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. , 1988, The Journal of rheumatology.

[16]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[17]  G. Rebecca,et al.  American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2011 .

[18]  H. Schumacher,et al.  A survey of current evaluation and treatment of gout. , 2006, The Journal of rheumatology.

[19]  S. Amur,et al.  Allopurinol pharmacogenetics: assessment of potential clinical usefulness. , 2011, Pharmacogenomics.

[20]  Hyon K. Choi,et al.  Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. , 2010, Arthritis and rheumatism.

[21]  G L C ELLISTON,et al.  Public Health Service , 1952 .

[22]  S. Ottaviani,et al.  [New therapeutic options for gout]. , 2011, Presse medicale.

[23]  M. A. van de Laar,et al.  Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol , 2008, Annals of the rheumatic diseases.

[24]  J. Heintzman,et al.  NSAID prescribing precautions. , 2009, American family physician.

[25]  A. Forsythe,et al.  Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy , 2011, Journal of medical economics.

[26]  T. Rainer,et al.  Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis , 2009, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[27]  G. Karachalios,et al.  Sulindac in the treatment of acute gout arthritis. , 1982, International journal of tissue reactions.

[28]  M. Janssen,et al.  Systemic corticosteroids for acute gout (Review) , 2008 .

[29]  Hyon K. Choi.  A prescription for lifestyle change in patients with hyperuricemia and gout , 2010, Current opinion in rheumatology.

[30]  R. Willburger,et al.  Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. , 2007, Rheumatology.

[31]  D. Nashel,et al.  Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. , 1993, The Journal of rheumatology.

[32]  R. Wortmann,et al.  Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. , 2010, Clinical therapeutics.

[33]  P. Lipsky,et al.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.

[34]  P. Macdonald,et al.  Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy , 2008, Nucleosides, nucleotides & nucleic acids.

[35]  K. Hande,et al.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.

[36]  C. Mancuso,et al.  Anakinra's efficacy is variable in refractory gout: report of ten cases. , 2010, Seminars in arthritis and rheumatism.

[37]  B. Joffe,et al.  Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study , 2000, Annals of the rheumatic diseases.

[38]  A. Forsythe,et al.  Chronic gout: epidemiology, disease progression, treatment and disease burden , 2010, Current medical research and opinion.

[39]  M. A. van de Laar,et al.  A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout , 2008, Annals of the rheumatic diseases.

[40]  M. Stevenson,et al.  Febuxostat for the Management of Hyperuricaemia in Patients with Gout , 2011, PharmacoEconomics.

[41]  庄司 晃.  A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy , 2005 .

[42]  R. Terkeltaub,et al.  Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. , 2012, Arthritis and rheumatism.

[43]  H. Schumacher,et al.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.

[44]  D. Goldfarb,et al.  Gout and its comorbidities. , 2010, Bulletin of the NYU hospital for joint diseases.

[45]  A. So,et al.  Extended Report , 2022 .

[46]  M. Gutierrez,et al.  Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study , 2011, Arthritis research & therapy.

[47]  Hyon K. Choi,et al.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.

[48]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[49]  J. Singh,et al.  Progress in Measurement Instruments for Acute and Chronic Gout Studies , 2009, The Journal of Rheumatology.

[50]  R. Terkeltaub.  Update on gout: new therapeutic strategies and options , 2010, Nature Reviews Rheumatology.

[51]  M. Doherty,et al.  Gout. Epidemiology of gout , 2010, Arthritis Research & Therapy.

[52]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[53]  D. Goldfarb,et al.  Prevalence of contraindications and prescription of pharmacologic therapies for gout. , 2011, The American journal of medicine.

[54]  N. Kleinman,et al.  The impact of gout on work absence and productivity. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[55]  A. Romanowicz,et al.  Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. , 1991, Current medical research and opinion.

[56]  S. Nicolaou,et al.  Dual energy computed tomography in tophaceous gout , 2008, Annals of the rheumatic diseases.

[57]  J. Jung,et al.  HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  J. Hodges,et al.  Quality of care for gout in the US needs improvement. , 2007, Arthritis and rheumatism.

[59]  Hyon K. Choi,et al.  Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide , 2011, Annals of the rheumatic diseases.

[60]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[61]  K. Chan,et al.  Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions , 2008, Pharmacotherapy.

[62]  F. Perez-Ruiz,et al.  Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial , 2012, The Journal of Rheumatology.

[63]  C. Cleeland,et al.  Lessons learned from a multiple-dose post-operative analgesic trial , 2004, Pain.

[64]  L. Kuller,et al.  Long-term cardiovascular mortality among middle-aged men with gout. , 2008, Archives of internal medicine.

[65]  H. Schumacher,et al.  Local ice therapy during bouts of acute gouty arthritis. , 2002, The Journal of rheumatology.

[66]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[67]  Gerald D. Groff,et al.  Systemic steroid therapy for acute gout: a clinical trial and review of the literature. , 1990, Seminars in arthritis and rheumatism.

[68]  K. Williams,et al.  Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? , 2012, Internal medicine journal.

[69]  P. Lucassen,et al.  Systemic corticosteroids for acute gout. , 2008, The Cochrane database of systematic reviews.

[70]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[71]  J. Allison,et al.  Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics. , 2004, Arthritis and rheumatism.

[72]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[73]  W. Willett,et al.  Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.

[74]  G. Gamble,et al.  Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography , 2008, Annals of the rheumatic diseases.

[75]  N. Dalbeth,et al.  Assessment of Tophus Size: A Comparison Between Physical Measurement Methods and Dual-Energy Computed Tomography Scanning , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[76]  M. González-Gay,et al.  Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout , 2010, Arthritis care & research.

[77]  A. Taniguchi,et al.  Comorbidities in Patients with Gout , 2011, Nucleosides, nucleotides & nucleic acids.

[78]  W. Bilker,et al.  Quality of care indicators for gout management. , 2004, Arthritis and rheumatism.

[79]  P. Brooks,et al.  Does colchicine work? The results of the first controlled study in acute gout. , 1987, Australian and New Zealand journal of medicine.

[80]  H. Schumacher,et al.  Dosing of antirheumatic drugs in renal disease and dialysis. , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[81]  P Netter,et al.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[82]  W. Willett,et al.  Fructose-rich beverages and risk of gout in women. , 2010, JAMA.

[83]  C. Vojir,et al.  Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents. , 2007, Journal of rehabilitation research and development.

[84]  J. Singh,et al.  Risk factors for gout and prevention: a systematic review of the literature , 2011, Current opinion in rheumatology.

[85]  N. Kleinman,et al.  The economic burden of gout on an employed population , 2006, Current medical research and opinion.

[86]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[87]  Roddy Edward,et al.  Gout , 2011 .

[88]  R. Terkeltaub,et al.  A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout , 2009, Current rheumatology reports.

[89]  Y. Moriwaki,et al.  Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism , 2003, Annals of the rheumatic diseases.

[90]  G. Lupton,et al.  The allopurinol hypersensitivity syndrome. , 1979, Journal of the American Academy of Dermatology.

[91]  I. F. Duff,et al.  Long term uricosuric therapy in gout. , 1962, Arthritis and rheumatism.

[92]  R. Terkeltaub,et al.  Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. , 2011, Arthritis and rheumatism.

[93]  M. Ernst,et al.  Management of gout in the older adult. , 2011, The American journal of geriatric pharmacotherapy.

[94]  D. Khanna,et al.  Health-Related Quality of Life and Outcome Measures in Gout , 2012 .

[95]  Hyon K. Choi,et al.  Purine-rich foods intake and recurrent gout attacks , 2012, Annals of the rheumatic diseases.

[96]  S. Navarra,et al.  Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. , 2004, Arthritis and rheumatism.

[97]  Hyon K. Choi,et al.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study , 2008, BMJ : British Medical Journal.

[98]  J. Scott,et al.  Multi-centre trial of naproxen and phenylbutazone in acute gout. , 1977, Advances in experimental medicine and biology.

[99]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[100]  J. Burgers,et al.  [Summary of the Dutch College of General Practitioners' (NHG) practice guideline 'The menopausal transition']. , 2012, Nederlands tijdschrift voor geneeskunde.

[101]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[102]  M. Abel,et al.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.

[103]  J. Brouwers,et al.  Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients , 2007, Clinical Rheumatology.

[104]  J. Singh,et al.  Developing a provisional definition of flare in patients with established gout. , 2012, Arthritis and rheumatism.

[105]  Robert G. Godfrey,et al.  Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.

[106]  D. Hunter,et al.  Alcohol consumption as a trigger of recurrent gout attacks. , 2006, The American journal of medicine.

[107]  D. Khanna.  American College of Rheumatology guidelines for management of gout , 2013 .

[108]  J. Boice,et al.  Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis , 2002, BMJ : British Medical Journal.

[109]  Elizabeth W Karlson,et al.  Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.

[110]  A. Hingorani,et al.  British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. , 2007, Rheumatology.

[111]  M. Doherty,et al.  Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study , 2012, Annals of the rheumatic diseases.

[112]  R. Terkeltaub,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.

[113]  M. Barclay,et al.  Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. , 2011, Arthritis and rheumatism.

[114]  R. Terkeltaub,et al.  Erratum: Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors; Association of PPP2CA Polymorphisms With Systemic Lupus Erythematosus Susceptibility in Multiple Ethnic Groups , 2011 .

[115]  H. Schumacher,et al.  Quality of Life and Disability in Patients with Treatment-Failure Gout , 2009, The Journal of Rheumatology.

[116]  Lily P. H. Yang.  Oral Colchicine (Colcrys®) , 2010, Drugs.

[117]  D. Furst,et al.  Gout and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[118]  R. Thiele,et al.  Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved , 2010, Rheumatology International.

[119]  S. Ottaviani,et al.  An exploratory ultrasound study of early gout. , 2011, Clinical and experimental rheumatology.

[120]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[121]  R. Terkeltaub,et al.  Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[122]  J. Coresh,et al.  Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. , 2012, Arthritis and rheumatism.

[123]  S. Andrade,et al.  Adherence with urate-lowering therapies for the treatment of gout , 2009, Arthritis research & therapy.

[124]  J. Peterson,et al.  Clinical utility of dual-energy CT for evaluation of tophaceous gout. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[125]  J. Sacristán,et al.  Allopurinol Hypersensitivity Syndrome: A Review , 1993, The Annals of pharmacotherapy.

[126]  P. Cameron,et al.  Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial , 2007, Annals of Emergency Medicine.

[127]  K. Gorter,et al.  [Summary of the Dutch College of General Practitioners' "Gout" Standard]. , 2002, Nederlands tijdschrift voor geneeskunde.

[128]  I. Reid,et al.  Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial , 2012, Annals of the rheumatic diseases.

[129]  W. Taylor,et al.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. , 2012, Arthritis and rheumatism.